Expression of SMARCD1 interacts with age in association with asthma control on inhaled corticosteroid therapy. by McGeachie, Michael J et al.
UCSF
UC San Francisco Previously Published Works
Title
Expression of SMARCD1 interacts with age in association with asthma control on inhaled 
corticosteroid therapy.
Permalink
https://escholarship.org/uc/item/5zn5v09p
Journal
Respiratory research, 21(1)
ISSN
1465-9921
Authors
McGeachie, Michael J
Sordillo, Joanne E
Dahlin, Amber
et al.
Publication Date
2020-01-28
DOI
10.1186/s12931-020-1295-4
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH Open Access
Expression of SMARCD1 interacts with age
in association with asthma control on
inhaled corticosteroid therapy
Michael J. McGeachie1 , Joanne E. Sordillo2, Amber Dahlin1, Alberta L. Wang1, Sharon M. Lutz2, Kelan G. Tantisira1,
Ronald Panganiban3, Quan Lu3, Satria Sajuthi4, Cydney Urbanek4, Rachel Kelly1, Benjamin Saef4, Celeste Eng5,
Sam S. Oh5, Alvin T. Kho6, Damien C. Croteau-Chonka1, Scott T. Weiss1, Benjamin A. Raby1,7, Angel C. Y. Mak4,
Jose R. Rodriguez-Santana8, Esteban G. Burchard4, Max A. Seibold5 and Ann Chen Wu2*
Abstract
Background: Global gene expression levels are known to be highly dependent upon gross demographic features
including age, yet identification of age-related genomic indicators has yet to be comprehensively undertaken in a
disease and treatment-specific context.
Methods: We used gene expression data from CD4+ lymphocytes in the Asthma BioRepository for Integrative
Genomic Exploration (Asthma BRIDGE), an open-access collection of subjects participating in genetic studies of
asthma with available gene expression data. Replication population participants were Puerto Rico islanders recruited
as part of the ongoing Genes environments & Admixture in Latino Americans (GALA II), who provided nasal brushings
for transcript sequencing. The main outcome measure was chronic asthma control as derived by questionnaires.
Genomic associations were performed using regression of chronic asthma control score on gene expression with age
in years as a covariate, including a multiplicative interaction term for gene expression times age.
Results: The SMARCD1 gene (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D
member 1) interacted with age to influence chronic asthma control on inhaled corticosteroids, with a doubling of
expression leading to an increase of 1.3 units of chronic asthma control per year (95% CI [0.86, 1.74], p = 6 × 10− 9),
suggesting worsening asthma control with increasing age. This result replicated in GALA II (p = 3.8 × 10− 8). Cellular
assays confirmed the role of SMARCD1 in glucocorticoid response in airway epithelial cells.
Conclusion: Focusing on age-dependent factors may help identify novel indicators of asthma medication response.
Age appears to modulate the effect of SMARCD1 on asthma control with inhaled corticosteroids.
Background
Asthma affects over 300 million persons globally and
costs more than $50 billion annually in the U.S. [1]
Despite effective treatment options, exacerbations from
asthma account for substantial preventable morbidity
[2]. Most individuals with asthma respond to inhaled
corticosteroids (ICS), the most effective asthma control-
ler medication, with significant symptom improvement;
however, approximately one third of individuals respond
minimally or not at all [3]. Furthermore, age appears to
modify ICS response, with increasing treatment failures
for each year over the age of 30 [4]. While genetics ex-
plains substantial variability in asthma drug disposition
and effects [5, 6], the field of pharmacogenomics has not
addressed the role of age in modulating response to
asthma medications.
Asthma pharmacogenomic studies to date have shed
light on biological mechanisms. For example, a genomic
study characterizing transcriptomes identified multiple
genes involved in the inflammatory pathway that influ-
ence ICS response including Cysteine Rich Secretory
Protein LCCL Domain Containing 2 (CRISPLD2) [7].
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CRISPLD2 mRNA has been shown to strongly vary with
age [8], and protein levels were shown to increase in
response to treatment with a known pro-inflammatory
cytokine, interleukin 1 beta (IL1β). Moreover, a tran-
scriptomic study of ORMDL Sphingolipid Biosynthesis
Regulator 3 (ORMDL3) found that a variant in that gene
might influence the route of anti-inflammatory action of
glucocorticoids by modifying the transcriptional acti-
vation of ORMDL3 in subjects with asthma [9]. As
ORMDL3 is associated with childhood-onset asthma,
ORMDL3’s influence on the inflammatory pathway may
be age-dependent; however, no published studies have
examined this [9].
Global gene expression levels are known to be highly
dependent upon gross demographic features including
age [10, 11], yet identification of age-related genomic
indicators has yet to be comprehensively undertaken in
an asthma-specific context. The objective of this study
was to discover genomic indicators specific to response
to ICS in individuals with asthma by accounting for age-
dependent genomic interactions.
Methods
Populations
We studied populations with available gene expression
data on subjects with asthma and ICS use. Data from
subjects in the Asthma BioRepository for Integrative
Genomic Exploration (Asthma BRIDGE) were used in
this study as the discovery population. Asthma BRIDGE
participants are taken from the EVE network of asthma
genetic studies [12]. In particular, the present analysis
focused on ICS-using participants from the CARE
[13, 14], CAG, and GRAAD [15] studies. These are
described in greater detail in the Additional file 1.
Secondary data analysis of these cohorts was approved
by the Partners Healthcare IRB, approval number HL-
71392-2. The replication population included Puerto
Rico islanders who were recruited as part of the ongoing
Genes environments & Admixture in Latino Americans
(GALA II) study described elsewhere [16, 17]. Asthma
was defined by a physician’s diagnosis and the presence of
2 or more symptoms of coughing, wheezing, or shortness
of breath in the 2 years before enrollment. Subjects who
reported ICS use in the past year were included. The study
was approved by local institutional review boards, and
written assent/consent was received from all subjects and
their parents.
Outcomes
We used a series of questions to assess asthma severity
and asthma control during the 6 months preceding
blood draw for the Asthma BRIDGE expression data.
Eleven questions regarding asthma severity and control
were combined into a single aggregate Chronic Asthma
Control Score (CACS). These questions were based on
the Asthma Control Questionnaire [18] and the Asthma
Control Test [19] questions, and are detailed in the
Additional file 1. The CACS score ranged from 0 (excel-
lent asthma control) to 44 (very poor asthma control).
In GALA II, the Childhood Asthma Control Test (C-
ACT) and the Asthma Control Questionnaire (ACQ)
[18] were used to derive a measure of asthma control.
Both the C-ACT and ACQ measure how well-controlled
a subject’s asthma is and can detect any changes in their
control, due to either spontaneous occurrence or result-
ing from treatment. Each questionnaire consists of 5
domains: nighttime symptoms, daytime symptoms,
activity limitations, use of rescue medication, and lung
function. The five domains were each categorized into
three levels of control: controlled (0), not well controlled
(1), or very poorly controlled (2). The asthma control
was determined to be the maximum value across the five
domains, with higher values indicating worse control.
Complete details are in Additional file 1: Table S2. In
this analysis, only subjects taking ICS in the previous
year were included, and the cohort was dichotomized
into the controlled group (0) and the poorly-controlled
group (1 or 2).
Expression data
We used mRNA expression data from CD4+ lympho-
cytes from the Asthma BioRepository for Integrative
Genomic Exploration (Asthma BRIDGE). This data was
previously processed on Illumina Human HT-12 v4
arrays, according to manufacturers’ protocol (Illumina,
San Diego CA). This array assays 47,036 different mRNA
features. These data were processed through quality
control metrics at Brigham and Women’s Hospital, as
described previously [20]. Asthma BRIDGE contains
gene expression data on several different cell types, and
for greatest power, we chose the CD4+ lymphocytes as
an asthma-relevant cell type that contains the highest
number of samples spanning an adult age-range. These
expression data have been previously described [20].
The GALA II expression data were obtained using
methods for nasal epithelial cell collection and processing
developed in collaboration with the National Institutes of
Health/National Institute of Allergy and Infectious Dis-
eases–sponsored Inner City Asthma Consortium, optimiz-
ing for collection and confirmation of columnar epithelial
cell type, RNA yield, and specimen-collector training [21].
Briefly, nasal epithelial cells were collected from behind
the inferior turbinate with a cytology brush using a nasal
illuminator. The collected brush was submerged in RLT
Plus lysis buffer plus β-mercaptoethanol and frozen at
− 80 °C until extraction. mRNA in samples were then quan-
tified using RNA-seq. The total read count of SMARCD1
was size factor-normalized followed by variance-stabilized
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transformation using the software package DESeq2 [22]
prior to modeling.
Statistical analysis
Clinical and demographic data were compared across
cohort subdivisions using analysis of variance (ANOVA)
for continuous outcomes and chi square tests for
discrete outcomes (Table 1).
Genomic associations were performed using linear
regression of CACS on log base 2 transformation of gene
expression with age in years as a covariate, including a
multiplicative interaction term for gene expression times
age. This interaction term was of principal interest to
the current study. Significance of association was assessed
by linear regression test using a significance threshold
of < 0.05 after Bonferroni correction. All operations were
performed in MATLAB R2018a (MathWorks, Natick, MA).
Replication of the SMARCD1 interaction with age in
GALA II was conducted with multinomial logistic re-
gression analysis using multinom R package with the
asthma control category as the outcome with the well-
controlled group as the baseline.
Individual top age times gene expression interaction
hits were interrogated using NDEX, a publically available
catalogue of biological networks [23].
In vitro verification
A549/NF-κB-luc reporter cells were transfected with
either scramble control or one of two SMARCD1 small
interfering RNAs (siRNA). These cells are responsive to
IL-1β stimulation, which is reduced by dexamethasone, a
glucocorticoid receptor agonist, indicating that these
cells exhibit glucocorticoid-mediated tethered trans-
repression of NF-κB [24]. 48 h post-transfection, the
cells were stimulated with 5 ng/mL IL-1β ± 5 nM Dexa-
methasone. Luciferase assays were performed after 18 h
treatment. The luciferase activity was normalized to its
own untreated scramble control. The luciferase activities
of cells treated with IL-1β + Dex and transfected with
siRNAs were calculated and compared to that of cells
treated with IL-1β + Dex and transfected with scramble
control. All experimental conditions were completed in
three replicates (n = 3).
Results
There were 118 subjects with gene expression data pass-
ing quality control from CD4+ lymphocytes in Asthma
BRIDGE who reported taking inhaled corticosteroids as
a controller medication in the previous year. These sub-
jects had mean Chronic Asthma Control Scores (CACS)
of 10.8 (+/− 6.9), shown in Fig. 1. A general trend
emerged showing increasing CACS with increasing age
(increase of 0.15/year, 95% confidence interval [0.079,
0.22], p = 3.4 × 10− 5), indicating worsening asthma con-
trol with advancing age. This trend remained significant
when stratified by sex, and no significant difference was
observed in males (increase of 0.17/year, 95% CI [0.065,
0.28], p = 0.0012) versus females (increase of 0.12/year,
95% CI [0.011, 0.22], p = 0.03).
In Asthma BRIDGE, the SMARCD1 gene (SWI/SNF-
related matrix-associated actin-dependent regulator of
chromatin subfamily D member 1) strongly interacted
with age to indicate higher CACS on inhaled corticoste-
roids, with a doubling of expression associated with an
Table 1 Cohorts included in Asthma BRIDGE. Continuous variables are reported as means with (+/− standard deviation). Binary
variables are reported as counts with (percentage of cohort)
GRAAD CAG CARE p-value
N 35 25 58
CACS 13.97 (+/− 8.01) 12.83 (+/− 6.38) 8.12 (+/− 5.16) 5.70E-05
Age 42.94 (+/− 12.70) 38.52 (+/− 13.35) 13.49 (+/− 3.45) 1.30E-29
Sex (# Male) 9 (25.71%) 6 (24.00%) 40 (68.97%) 1.10E-05
Race
Non-Hispanic White 0 (0.00%) 4 (16.00%) 35 (60.34%) 2.00E-09
African American 30 (85.71%) 20 (80.00%) 8 (13.79%) 3.70E-13
Hispanic 0 (0.00%) 0 (0.00%) 9 (15.52%) 0.0065
Other/Mixed 5 (14.29%) 1 (4.00%) 6 (10.34%) 0.43
Age Asthma Onset 18.25 (+/− 16.22) 5.73 (+/− 7.79) 2.16 (+/− 2.09) 1.50E-11
Atopy 12 (34.29%) 9 (36.00%) 34 (58.62%) 0.036
Intra-Uterine Smoke 5 (14.29%) 5 (20.00%) 3 (5.17%) 0.11
Environmental Smoke Exposure 21 (60.00%) 12 (48.00%) 9 (15.52%) 2.80E-05
Ever Smoker 13 (37.14%) 3 (12.00%) 0 (0.00%) 2.60E-06
P-values for continuous outcomes are from ANOVA, binary outcomes are from chi-squared tests. CACS: Chronic Asthma Control Score. CARE: Childhood Asthma
Research and Education study. CAG: Chicago Asthma Genetics study. GRAAD: Genomic Research on Asthma in the African Diaspora
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increase of 1.3 units of CACS per year increase in age
(95% CI [0.86, 1.74], p = 6 × 10− 9), indicating increasing
importance of SMARCD1 with advancing age (Fig. 2). In
the replication population, GALA II, the age-by-
SMARCD1 interaction was associated with poorly-
controlled asthma compared to subjects with controlled
asthma, with a ratio of odds ratios relative to control of
1.72 (95% CI [1.42, 2.10], p = 3.8 × 10− 8), indicating in-
creasing probability of being in the poorly-controlled
group with age.
We observed that both the specific study within
Asthma BRIDGE and self-identified race were strongly
Fig. 1 Chronic Asthma Control Score (CACS) by Age, stratified by sex. Shown are trend lines along with the distribution of CACS by age. Both
trendlines are significant
Fig. 2 Blue: Asthma BRIDGE participants younger than 30 years; Red: Asthma BRIDGE participants 31–50 years old; Yellow: Asthma BRIDGE
participants 50 years or older. Differing slopes indicates interaction of SMARCD1 with Age on CACS
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split by age (Table 1): GRAAD and CAG are adult studies
and CARE is a study of children. Similarly, CARE is pre-
dominantly non-Hispanic white with a minority popula-
tion of Hispanic white; while GRAAD and CAG are
mostly African American. Since we wanted to focus on
the interaction between gene expression and age in
asthma control, we did not include either of these demo-
graphic variables in our main analysis. However, there was
no significant association of race or study with SMARCD1
expression after adjustment for age (ANOVA, p = 0.29
and p = 0.3, respectively).
For completeness, we also considered SMARCD1-age
interaction in other cell types available in ABRIDGE.
These included (1) Alveolar Macrophages (n = 33, p = .75),
although these samples did not span a similar age range
(ages 8 to 22 years). (2) Bronchial Epithelium (n = 16,
p = .2), Bronchoalveolar cells (n = 12, p = .22), and whole
blood (n = 4, p not computed), although these had low
sample sizes. Finally (5) CD4+ lymphocytes stimulated
with hemagglutinin (n = 139, p = .01), although this stimu-
lation may not be representative of asthma biology.
To investigate whether SMARCD1 plays a role in the
inflammatory response as well as in the anti-inflammatory
action of corticosteroids in vitro, we knocked down
SMARCD1 in a human lung epithelial cell line (similar to
the replication samples which were enriched for airway
epithelium) stably expressing nuclear factor-kappa B (NF-
κB) luciferase reporter [24]. We transfected this reporter
cell line with two different SMARCD1 siRNAs. One of
these resulted in a large (greater than 80%) reduction of
SMARCD1 expression relative to scramble-control siRNA
transfection (Fig. 3). In this successful knockdown of
SMARCD1, we observed a significant increase in luciferase
activity relative to scramble-control in response to both
IL-1β stimulation (p < 0.01) and IL-1β plus dexametha-
sone (p < 0.01) (Fig. 4). This verified that, at least in vitro,
SMARCD1 is an important part of the inflammatory
response and its absence increases the anti-inflammatory
action of corticosteroid treatment.
In addition to performing pathway enrichment studies
using our own results (see Additional file 1), we also in-
vestigated connections of the SMARCD1 gene and its
protein product (also labeled SMARCD1) in NDEX, a
searchable collection of gene expression and protein-
protein interaction networks from multiple network and
pathway databases [23]. A search on SMARCD1 revealed
the following biologically relevant network for our
phenotype of interest, ICS response, in the current ana-
lysis: The glucocorticoid receptor regulatory network (a
protein-protein interaction network) was derived from
the latest BioPAX3 version of the Pathway Interaction
Database. A portion of the larger network including our
gene of interest (the one-step adjacent network sur-
rounding SMARCD1) is shown in Fig. 5. This diagram
indicates that cortisol is a controller of SMARCD1, and
that expression of SMARCD1 is related to SGK1 (gluco-
corticoid regulated kinase 1) the glucocorticoid receptor
Nuclear Receptor Subfamily 3 Group C Member 1
(NR3C1).
Discussion
Our study has three key findings. First, age appears to
modulate the association of SMARCD1 with chronic
asthma control. Secondly, focusing on age-dependent
factors is likely to yield important indicators of asthma
medication response. Third, interactions between age
and expression of SMARCD1 in CD4+ lymphocytes were
replicated in nasal samples enriched for respiratory epi-
thelial cells, suggesting that the potential age-dependent
effects of SMARCD1 on asthma control could be medi-
ated by systemic as well as locally induced changes in
the airways. That SMARCD1 interacts with age to affect
asthma control on ICS, across two different cell types, in
two different racial ancestry groups, and using two
different measures of asthma control, indicates a robust
effect.
SMARCD1, a member of the SWI/SNF chromatin re-
modeling complex family, regulates gene transcription
by binding specific transcriptional factors and altering
local chromatin structure [25]. To our knowledge,
SMARCD1 has not been reported as associated with ICS
response in prior studies, although it has been found to
be associated with asthma in a prior analysis that used
GEO data from adult cohorts of the Unbiased Biomarkers
for the Predictions of Respiratory Disease Outcomes (U-
BIOPRED) research study [26]. Protein-protein interaction
network data support the role of SMARCD1 in modulat-
ing asthma control while on ICS. Synthetic glucocorticoid
medications (such as inhaled budesonide and dexametha-
sone) are potent inducers of glucocorticoid signaling,
Fig. 3 Relative expression of SMARCD1 in A549 cells after transfection
with two separate short interfering RNAs (siRNA). siRNA 1 showed over
80% reduction of SMARCD1 expression compared to transfection with
a scramble RNA control
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exerting their anti-inflammatory effects through gluco-
corticoid receptor binding [27]. A search of NDEX [23]
shows SMARCD1 as a key effector and regulatory protein
within the glucocorticoid receptor regulatory network. In
protein-protein interaction studies, SMARCD1 complexes
with NRC31 (nuclear receptor subfamily 3 group C mem-
ber 1), a glucocorticoid receptor [28]. We further validated
the in vitro role of SMARCD1 in the inflammatory process
and the action of dexamethasone on that process.
In addition to its direct involvement in glucocorticoid
signaling, SMARCD1 is also associated with apoptosis
pathways [29, 30]. Interestingly, in vitro studies of ICS
response have identified apoptosis as a potential protect-
ive mechanism associated with resolution of asthmatic
inflammation [31–34]. An analysis of gene regulatory
networks for ICS response in mid-childhood identified
enrichment of pro-apoptosis pathways in good ICS
responders, and anti-apoptosis pathway enrichment in
poor ICS responders. While cellular apoptosis is a na-
tural process occurring at all stages of human develop-
ment, changes in expression of apoptosis genes occur
with age [35, 36]. In our study, alterations in SMARCD1
expression with age may relate to its involvement in
apoptosis pathways. Future studies will be required to
understand whether age-associated changes in apoptosis
pathways underlie the age-related effects of SMARCD1
on ICS response in asthmatics.
Our study has several strengths. Our gene expression
analysis was appropriately timed to recent inhaled cor-
ticosteroid use. In our discovery analysis, asthma control
while on ICS was assessed using a questionnaire based
Fig. 4 Luciferase activity of A549/NF-κB-luc reporter cells transfected with either scramble control or one of two SMARCD1 small interfering RNAs
(siRNA). Cells were stimulated with 5 ng/mL IL-1βwith and without 5 nM Dexamethasone (dex). The luciferase activities of cells treated with IL-
1β + dex and transfected with siRNAs were calculated and compared to that of cells treated with IL-1β + dex and transfected with scramble
control. * Indicates significant differences at p < 0.05
Fig. 5 SMARCD1 nearest-neighbor adjacency subnetwork with the
glucocorticoid receptor response pathway. The orange arrow
originating from cortisol to SMARCD1 indicates that cortisol is a
controller of SMARCD1. The blue directed edge from SMARCD1 to
SGK1 (glucocorticoid regulated kinase 1) demonstrates the known
relationship between SMARCD1 expression and increased expression
of SGK1. The gray dotted lines indicate that SMARCD1 co-complexes
with the connected node proteins, including Nuclear Receptor
Subfamily 3 Group C Member 1 (NR3C1), a glucocorticoid receptor
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on the ACT criteria, which accounts for multiple aspects
of control, including symptoms, quality of life metrics
(missed school/work), medication use and health care
utilization (emergency room/doctor visits for asthma). In
addition to replication across tissue types, we found
replication of the SMARCD1 by age interaction across
multiple racial ethnic groups, which contributes to the
generalizability of our findings. Our study also had some
limitations. Assessment of asthma control was somewhat
different in the discovery and replication cohorts, which
may have affected our ability to replicate additional
age-by-gene expression interactions in models of
asthma control while on ICS. Although our in vitro val-
idation demonstrated a biological relationship between
SMARCD1, NF-kB, and dexamethasone, the nature of
the experiment with cell lines precludes the assessment
of age; thus this result does not directly support a dif-
ferential effect of SMARCD1 with increasing age. Fur-
thermore, this effect was in the opposite direction as
one might expect: SMARCD1 knockdown increased
NF-kB, which generally increases inflammation, which
generally increases asthma symptoms, and would lead
to higher CAC. We speculate that this difference in
effect direction could be due to differences between
in vitro and in vivo conditions, the inability to include
age in the cell lines, or differences between airway
epithelial cells and CD4+ lymphocytes. However, our
strongest evidence indicates that increasing SMARCD1
is associated with worsening asthma control.
Conclusions
In conclusion, our study provides evidence that focusing
on age-dependent factors may help identify novel indicators
of asthma medication response. Age appears to modulate
the association of SMARCD1 with asthma control in sub-
jects taking inhaled corticosteroids.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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